Health service planning

TOTAL CARE PLAN: BSC

GRGDSP (TFA) is an integrin inhibitor.Appearance:SolidIC50&amp: Target:Integrin .In Vitro:It is demonstrated that transarterial infusion of GRGDSP (Gly-Arg-Gly-Asp-Ser-Pro integrin-inhibitor which includes RGD-peptide). As a synthetic linear RGD

GRGDSP (TFA) is an integrin inhibitor.Appearance:SolidIC50&amp: Target:Integrin .In Vitro:It is demonstrated that transarterial infusion of GRGDSP (Gly-Arg-Gly-Asp-Ser-Pro integrin-inhibitor which includes RGD-peptide). As a synthetic linear RGD

GRGDSP (TFA) is an integrin inhibitor.Appearance:SolidIC50&amp: Target:Integrin .In Vitro:It is demonstrated that transarterial infusion of GRGDSP (Gly-Arg-Gly-Asp-Ser-Pro integrin-inhibitor which includes RGD-peptide). As a synthetic linear RGD

dFKBP-1 is a potent and PROTAC-based FKBP12 degrader. dFKBP-1 incorporates the ligand SLF ( HY-114872 ) of FKBP12 , the Thalidomide based Cereblon ligand and a linkerIn VitrodFKBP-1 potently decreases FKBP12 abundance in MV4:11 cells, leading to

dFKBP-1 is a potent and PROTAC-based FKBP12 degrader. dFKBP-1 incorporates the ligand SLF ( HY-114872 ) of FKBP12 , the Thalidomide based Cereblon ligand and a linkerIn VitrodFKBP-1 potently decreases FKBP12 abundance in MV4:11 cells, leading to

dFKBP-1 is a potent and PROTAC-based FKBP12 degrader. dFKBP-1 incorporates the ligand SLF ( HY-114872 ) of FKBP12 , the Thalidomide based Cereblon ligand and a linkerIn VitrodFKBP-1 potently decreases FKBP12 abundance in MV4:11 cells, leading to

TOTAL CARE PLAN: ULT DEVLNK - LPD Service Plans, Full Coverage Contract

TOTAL CARE PLAN: CRYO - LPD Service Plans, Full Coverage Contract

TRAXXEKG License - Full analytics/advance predictive - Other Cold Storage, Insight (G3)